951174-48-4

Basic information

• Product Name: (S)-3-amino-3-(4-biphenyl)propanoic acid
• CAS NO: 951174-48-4
• Molecular Weight: 241.29
• Mol File: 951174-48-4.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: (S)-3-amino-3-(4-biphenyl)propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-amino-3-(4-biphenyl)propanoic acid(951174-48-4)
• EPA Substance Registry System: (S)-3-amino-3-(4-biphenyl)propanoic acid(951174-48-4)

Safety Data

• Hazardous Substances Data: 951174-48-4(Hazardous Substances Data)

Usage

Description

(S)-3-amino-3-(4-biphenyl)propanoic acid is a chiral chemical compound characterized by the presence of an amino group, a biphenyl group, and a propanoic acid group. This unique structure endows it with potential applications in various fields, particularly the pharmaceutical industry, where it can be utilized in the development of new drugs. Its distinct properties and chiral nature make it a subject of interest for researchers working on chiral synthesis and the creation of pharmacologically active compounds. Furthermore, its structure may also prove beneficial in organic chemistry research and development, serving as a valuable building block for synthesizing a range of organic compounds with potential pharmaceutical and industrial applications.

Uses

Used in Pharmaceutical Industry:
(S)-3-amino-3-(4-biphenyl)propanoic acid is used as a key intermediate for the synthesis of various pharmaceutical compounds due to its unique structure and chiral properties. Its incorporation into drug molecules can potentially enhance their efficacy and selectivity, leading to improved therapeutic outcomes.
Used in Chiral Synthesis Research:
As a chiral molecule, (S)-3-amino-3-(4-biphenyl)propanoic acid is used as a model compound in the study of chiral synthesis. Researchers utilize it to develop new methods and techniques for the synthesis of enantiomerically pure compounds, which are essential in the pharmaceutical industry to avoid the potential adverse effects of their mirror images.
Used in Organic Chemistry Research and Development:
(S)-3-amino-3-(4-biphenyl)propanoic acid serves as a useful building block in the synthesis of a variety of organic compounds. Its unique structure allows for the creation of novel molecules with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Drug Design and Development:
(S)-3-amino-3-(4-biphenyl)propanoic acid's specific properties and structure make it an attractive candidate for drug design and development. It can be used as a starting material or a structural component in the creation of new drugs, particularly those targeting specific biological receptors or pathways.

Upstream product

• 141-82-2 malonic acid 
• 3218-36-8 4-Phenylbenzaldehyde 
• 479591-57-6 3-amino-3-(4-biphenyl)propionic acid methyl ester 
• 910574-67-3 tert-butyl(E)-3-([1,1′-biphenyl]-4-yl)acrylate 
• 951174-33-7 tert-butyl (3S,αR)-3-(N-benzyl-N-α-methylbenzylamino)-3-(4-biphenyl)propanoate 
• 951174-45-1 tert-butyl (S)-3-amino-3-(4-biphenyl)propanoate 
• 951174-25-7 tert-butyl (3R,αS)-3-(N-benzyl-N-α-methylbenzylamino)-3-(4-biphenyl)propanoate 
• 951174-42-8 tert-butyl (R)-3-amino-3-(4-biphenyl)propanoate 

Relevant articles and documents

Catalytic asymmetric oxidative carbonylation-induced kinetic resolution of sterically hindered benzylamines to chiral isoindolinones

A highly enantioselective kinetic resolution of sterically hindered benzylamines has been achieved for the first time through transition-metal-catalyzed oxidative carbonylation, in which the new KR strategy offered a new approach to afford chiral isoindolinones (er up to 97?:?3) and the origin of chemoselectivity and stereoselectivity was confirmed by density functional theory (DFT) calculations.

Structure activity relationships of αv integrin antagonists for pulmonary fibrosis by variation in aryl substituents

Antagonism of αvβ6 is emerging as a potential treatment of idiopathic pulmonary fibrosis based on strong target validation. Starting from an αvβ3 antagonist lead and through simple variation in the nature and position of the aryl substituent, the discovery of compounds with improved αvβ6 activity is described. The compounds also have physicochemical properties commensurate with oral bioavailability and are high quality starting points for a drug discovery program. Compounds 33S and 43E1 are pan αv antagonists having ca. 100 nM potency against αvβ3, αvβ5, αvβ6, and αvβ8 in cell adhesion assays. Detailed structure activity relationships with these integrins are described which also reveal substituents providing partial selectivity (defined as at least a 0.7 log difference in pIC50 values between the integrins in question) for αvβ3 and αvβ5.

Parallel synthesis of homochiral β-amino acids

The parallel asymmetric synthesis of an array of 30 β-amino acids of high enantiomeric purity using the conjugate addition of homochiral lithium N-benzyl-N-(α-methylbenzyl)amide as the key step is accomplished. The experimental simplicity and highly practical nature of the protocol is demonstrated by the efficient parallel conversion of 15 α,β-unsaturated esters to both enantiomeric series of the corresponding β-amino acids in high overall yields and selectivities with minimal purification involved in each step of the reaction protocol.